Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, wh… Read more
Hikal Limited (HIKAL) - Net Assets
Latest net assets as of September 2025: ₹11.94 Billion INR
Based on the latest financial reports, Hikal Limited (HIKAL) has net assets worth ₹11.94 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹23.49 Billion) and total liabilities (₹11.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹11.94 Billion |
| % of Total Assets | 50.84% |
| Annual Growth Rate | 12.18% |
| 5-Year Change | 35.24% |
| 10-Year Change | 123.9% |
| Growth Volatility | 24.43 |
Hikal Limited - Net Assets Trend (2005–2025)
This chart illustrates how Hikal Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hikal Limited (2005–2025)
The table below shows the annual net assets of Hikal Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹12.62 Billion | +6.29% |
| 2024-03-31 | ₹11.88 Billion | +4.78% |
| 2023-03-31 | ₹11.33 Billion | +6.13% |
| 2022-03-31 | ₹10.68 Billion | +14.42% |
| 2021-03-31 | ₹9.33 Billion | +14.32% |
| 2020-03-31 | ₹8.17 Billion | +7.97% |
| 2019-03-31 | ₹7.56 Billion | +12.97% |
| 2018-03-31 | ₹6.69 Billion | +10.65% |
| 2017-03-31 | ₹6.05 Billion | +7.31% |
| 2016-03-31 | ₹5.64 Billion | +5.88% |
| 2015-03-31 | ₹5.32 Billion | +5.50% |
| 2014-03-31 | ₹5.05 Billion | +12.09% |
| 2013-03-31 | ₹4.50 Billion | +4.57% |
| 2012-03-31 | ₹4.31 Billion | +7.52% |
| 2011-03-31 | ₹4.00 Billion | +3.97% |
| 2010-03-31 | ₹3.85 Billion | +5.62% |
| 2009-03-31 | ₹3.65 Billion | +110.97% |
| 2008-03-31 | ₹1.73 Billion | -6.01% |
| 2007-03-31 | ₹1.84 Billion | -1.83% |
| 2006-03-31 | ₹1.87 Billion | +47.81% |
| 2005-03-31 | ₹1.27 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hikal Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2187.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹9.67 Billion | 76.61% |
| Common Stock | ₹247.00 Million | 1.96% |
| Other Comprehensive Income | ₹514.00 Million | 4.07% |
| Other Components | ₹2.19 Billion | 17.36% |
| Total Equity | ₹12.62 Billion | 100.00% |
Hikal Limited Competitors by Market Cap
The table below lists competitors of Hikal Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bancorp. of Southern Indiana
PINK:BCSO
|
$74.68 Million |
|
ISU Abxis Co. Ltd
KQ:086890
|
$74.70 Million |
|
Sao Ta Foods JSC
VN:FMC
|
$74.70 Million |
|
JUKCF
PINK:JUKCF
|
$74.72 Million |
|
HYUNDAI FEED Inc
KQ:016790
|
$74.65 Million |
|
Intai Technology
TWO:4163
|
$74.64 Million |
|
Koenig & Bauer AG
XETRA:SKB
|
$74.62 Million |
|
Summit State Bank
NASDAQ:SSBI
|
$74.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hikal Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,876,610,000 to 12,623,000,000, a change of 746,390,000 (6.3%).
- Net income of 908,000,000 contributed positively to equity growth.
- Dividend payments of 148,000,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹908.00 Million | +7.19% |
| Dividends Paid | ₹148.00 Million | -1.17% |
| Other Changes | ₹-13.61 Million | -0.11% |
| Total Change | ₹- | 6.28% |
Book Value vs Market Value Analysis
This analysis compares Hikal Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.38x to 1.66x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹9.24 | ₹169.79 | x |
| 2006-03-31 | ₹15.10 | ₹169.79 | x |
| 2007-03-31 | ₹14.80 | ₹169.79 | x |
| 2008-03-31 | ₹13.18 | ₹169.79 | x |
| 2009-03-31 | ₹28.60 | ₹169.79 | x |
| 2010-03-31 | ₹29.92 | ₹169.79 | x |
| 2011-03-31 | ₹31.69 | ₹169.79 | x |
| 2012-03-31 | ₹34.92 | ₹169.79 | x |
| 2013-03-31 | ₹36.52 | ₹169.79 | x |
| 2014-03-31 | ₹40.93 | ₹169.79 | x |
| 2015-03-31 | ₹43.19 | ₹169.79 | x |
| 2016-03-31 | ₹45.72 | ₹169.79 | x |
| 2017-03-31 | ₹49.07 | ₹169.79 | x |
| 2018-03-31 | ₹54.29 | ₹169.79 | x |
| 2019-03-31 | ₹61.33 | ₹169.79 | x |
| 2020-03-31 | ₹66.22 | ₹169.79 | x |
| 2021-03-31 | ₹75.70 | ₹169.79 | x |
| 2022-03-31 | ₹86.62 | ₹169.79 | x |
| 2023-03-31 | ₹91.93 | ₹169.79 | x |
| 2024-03-31 | ₹96.24 | ₹169.79 | x |
| 2025-03-31 | ₹102.32 | ₹169.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hikal Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.19%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.88%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 2.00x
- Recent ROE (7.19%) is below the historical average (12.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 34.18% | 10.72% | 0.77x | 4.16x | ₹252.72 Million |
| 2006 | 19.63% | 7.35% | 0.80x | 3.35x | ₹164.47 Million |
| 2007 | 11.41% | 4.38% | 0.73x | 3.57x | ₹23.65 Million |
| 2008 | 30.17% | 9.90% | 0.62x | 4.88x | ₹317.14 Million |
| 2009 | 11.52% | 7.12% | 0.52x | 3.10x | ₹53.87 Million |
| 2010 | 13.05% | 9.33% | 0.51x | 2.73x | ₹117.61 Million |
| 2011 | 9.28% | 7.40% | 0.47x | 2.66x | ₹-28.78 Million |
| 2012 | 10.69% | 6.51% | 0.62x | 2.63x | ₹29.74 Million |
| 2013 | 5.61% | 3.83% | 0.55x | 2.65x | ₹-197.82 Million |
| 2014 | 12.66% | 7.72% | 0.65x | 2.52x | ₹134.28 Million |
| 2015 | 7.59% | 4.70% | 0.66x | 2.43x | ₹-128.43 Million |
| 2016 | 7.31% | 4.54% | 0.71x | 2.26x | ₹-151.77 Million |
| 2017 | 11.19% | 6.55% | 0.75x | 2.28x | ₹72.18 Million |
| 2018 | 11.54% | 5.95% | 0.84x | 2.30x | ₹102.89 Million |
| 2019 | 13.63% | 6.49% | 0.94x | 2.23x | ₹274.54 Million |
| 2020 | 10.34% | 5.61% | 0.85x | 2.17x | ₹27.85 Million |
| 2021 | 14.26% | 7.80% | 0.89x | 2.05x | ₹398.00 Million |
| 2022 | 15.03% | 8.33% | 0.87x | 2.07x | ₹537.01 Million |
| 2023 | 6.92% | 3.91% | 0.84x | 2.10x | ₹-349.65 Million |
| 2024 | 5.86% | 3.94% | 0.71x | 2.09x | ₹-491.64 Million |
| 2025 | 7.19% | 4.88% | 0.74x | 2.00x | ₹-354.30 Million |
Industry Comparison
This section compares Hikal Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hikal Limited (HIKAL) | ₹11.94 Billion | 34.18% | 0.97x | $74.67 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |